	US 12,270,053 B2
	Nano-engineered therapeutic stealth cells
Daniel Gallego-Perez, Columbus, OH (US); William Carson, Hilliard, OH (US); Silvia M. Duarte Sanmiguel, Columbus, OH (US); and Natalia Higuita-Castro, Columbus, OH (US)
Assigned to Ohio State Innovation Foundation, Columbus, OH (US)
Appl. No. 17/283,745
Filed by Ohio State Innovation Foundation, Columbus, OH (US)
PCT Filed Oct. 18, 2019, PCT No. PCT/US2019/056988 § 371(c)(1), (2) Date Apr. 8, 2021, PCT Pub. No. WO2020/081966, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/747,980, filed on Oct. 19, 2018.
Prior Publication US 2021/0380949 A1, Dec. 9, 2021
Int. Cl. C12N 5/09 (2010.01); A61K 35/13 (2015.01); A61K 35/15 (2015.01); A61K 39/00 (2006.01); C07K 14/81 (2006.01)

CPC C12N 5/0693 (2013.01) [A61K 35/13 (2013.01); A61K 35/15 (2013.01); A61K 39/461 (2023.05); A61K 39/4621 (2023.05); A61K 39/464499 (2023.05); C07K 14/8146 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/49 (2023.05); C12N 2509/10 (2013.01); C12N 2510/00 (2013.01); C12Y 304/24017 (2013.01)]

10 Claims

1. A method for producing a therapeutic stealth cell, comprising (a) sorting myeloid-derived suppressor cells (MDSCs) from a sample from a subject for a subpopulation of the granulocytic CD11b+Ly6C^loLy6G+ MDSCs; and (b) reprogramming the subpopulation of MDSCs to deliver anti-cancer agents.